注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
United Therapeutics Corp是一家生物技术公司。该公司专注于产品的开发和商业化,以满足慢性病和危及生命的疾病患者未满足的医疗需求。该公司在美国营销和销售四种治疗肺动脉高压(PAH)的商业疗法:Remodulin(曲前列环素)注射液、包括Tyvaso吸入系统的Tyvaso(曲前列环素)吸入溶液、Orenitram(曲前列环素)缓释片和Adcirca(他达拉非)片剂。该公司还在美国营销和销售肿瘤产品Unituxin(dinutuximab)注射液,该注射液被批准用于治疗高危神经母细胞瘤,以及Remodulin的Remunity Pump。该公司还从事再生医学、异种移植、离体肺灌注等多项器官移植相关技术的早期研发。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Martine A. Rothblatt | 68 | 1996 | Founder, Chairman & CEO |
Christopher Causey | 60 | 2003 | Independent Director |
Raymond A. Dwek | 81 | 2002 | Independent Director & Member of the Scientific Advisory Board |
Christopher Patusky | 59 | 2002 | Independent Vice Chairman & Lead Independent Director |
Louis W. Sullivan | 90 | 2002 | Independent Director & Member of the Scientific Advisory Board |
Raymond C. Kurzweil | 75 | 2002 | Independent Director |
Thomas G. Thompson | 81 | 2010 | Independent Director |
Katherine J. Klein | 66 | 2014 | Independent Director |
Mardi Gomberg-Maitland | - | - | Member of the Scientific Advisory Board |
Robert C. Bourge | - | - | Member of the Scientific Advisory Board |
Magdi H. Yacoub | 87 | - | Member of the Scientific Advisory Board |
Linda Maxwell | 48 | 2020 | Independent Director |
Richard Giltner | 59 | 2009 | Independent Director |
Judy D. Olian | 71 | 2015 | Independent Director |
Samuel O. Thier | 85 | - | Member of the Scientific Advisory Board |
Nilda Mesa | 63 | 2018 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核